Please assess the completion status of the following clinical trial:

Trial Title: Determining Risk Factors for Successful PPI Weaning

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years old~* Male or female~* PPI on home medication reconciliation~* GERD that is symptom controlled (per questionnaire), OR~* Gastritis that is symptom controlled (per questionnaire), OR~* An unclear indication for PPI use but free of GERD/gastritis/ulcer symptoms (includes patients on GI prophylaxis from the hospital and continued medication)~* Desire or willingness to be off of PPI chronically~* On PPI chronically (\> 2 months or 8 weeks, can be intermittent use)~* Initial PPI dose cannot exceed more than the equivalent of Omeprazole 40mg PO BID~* Comprehend English well (per provider's discretion; to understand questionnaires, instructions, etc.)~Exclusion Criteria:~* On PPI for fewer than 2 months~* Co-morbid diagnosis of Peptic Ulcer Disease, H.pylori infection, Barrett's esophagus, malignancy, Inflammatory Bowel Disease~* Diagnosis of moderate to severe renal impairment (defined as CrCl \<50 mL/min; reasoning due to caution of H2RB on renal failure)~* Diagnosis of prolonged QT interval with renal impairment (reasoning due to H2RB with concomitant renal failure may increase QT interval if not renally dosed)~* True allergy to Proton Pump Inhibitor and / or H2 Receptor Blocker~* Patients with frequent cardiac angina symptoms (decreasing the dose of PPI may cause rebound GERD and the patient may think they are having a heart attack)~* Pregnant women, fetuses, neonates or fetal material~* Females of reproductive potential at time of research that are not on a form on birth control (OCPs, tubal ligation, etc) or lactating~* Adults with decisional impairment~* Prisoners~* Patients with uncontrolled Psychological illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PPI Taper (Type: OTHER): PPI Taper using Lifestyle Modifications, per study protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).